New Delhi, May 16, 2025: Jubilant Pharmova Ltd has reported a significant turnaround in its financial performance for the fourth quarter and full fiscal year ended March 31, 2025. The pharmaceutical major posted a consolidated net profit of ₹151.3 crore in Q4 FY25, marking a strong recovery from the net loss of ₹61.8 crore reported in the same period last year.
Q4 FY25 Financial Highlights
The company’s total revenue from operations during the quarter rose to ₹1,928.8 crore, up from ₹1,758.6 crore in Q4 FY24. However, total expenses also increased to ₹1,731.3 crore, compared to ₹1,661.2 crore in the year-ago period.
| Particulars | Q4 FY25 | Q4 FY24 | YoY Change |
|---|
| Net Profit / (Loss) | ₹151.3 crore | ₹(61.8) crore | Significant turnaround |
| Revenue from Operations | ₹1,928.8 crore | ₹1,758.6 crore | +9.7% |
| Total Expenses | ₹1,731.3 crore | ₹1,661.2 crore | +4.2% |
Full Year FY25 Performance
For the full fiscal year FY25, Jubilant Pharmova reported a consolidated net profit of ₹836.3 crore, a dramatic increase from ₹72.7 crore in FY24. Revenue from operations for the year stood at ₹7,234.5 crore, compared to ₹6,702.9 crore in the previous financial year.
| Particulars | FY25 | FY24 | YoY Change |
|---|
| Net Profit | ₹836.3 crore | ₹72.7 crore | +1050.5% |
| Revenue from Operations | ₹7,234.5 crore | ₹6,702.9 crore | +7.9% |
Dividend Declaration
The board of directors has recommended a final dividend of ₹5 per equity share of face value ₹1 each for the financial year ended March 31, 2025, reinforcing the company’s positive outlook and commitment to shareholder returns.
Jubilant Pharmova’s performance signals a strong recovery and operational growth across its business segments, positioning it well for sustained momentum in the upcoming fiscal year.